| | Variable | Median survival (months) (95% CI) | P value* | 2-year survival (%) | 5-year survival (%) |
| | Sex | | 0.84 | | | | Female | 28 (3, 106) | | 57.1 | 21.4 | | Male | 23 (14, 26) | | 45.0 | 20.9 | | Race and ethnicity | | 0.01 | | | | Non-Hispanic, white | 20 (12, 25) | | 39.5 | 18.6 | | Hispanic white | 56 (26, 128) | | 70.0 | 32.5 | | Black | 8 (2, 23) | | 23.5 | 5.9 | | Smoking status | | 0.32 | | | | Nonsmoker | 23 (13, 31) | | 47.5 | 19.7 | | Ex-smoker | 17 (8, 28) | | 43.2 | 21.6 | | Current smoker | 36 (13, 134) | | 61.9 | 28.6 | | Unknown | 15 (4, 26) | | 33.3 | 16.7 | | Age at diagnosis, years (range) | | 0.34 | | | | 21–40 | 22 (10, 26) | | 43.0 | 28.0 | | 41–60 | 18 (9, 26) | | 39.0 | 22.0 | | 61–80 | 38 (4, 128) | | 61.0 | 46.0 | | >80 | 32 (12, 88) | | 65.0 | 31.0 | | Year of Kaposi’s diagnosis | | 0.004 | | | | 1987–1996 | 14 (9, 23) | | 35.0 | 12.0 | | 1997–2007 | 87 (38, —) | | 65.0 | 56.0 | | Site of initial presentation | | 0.04 | | | | Skin | 23 (20, 28) | | 48.0 | 29.0 | | Nonskin | 9 (3, 26) | | 30.0 | 29.0 | | Stage at Diagnosis | | 0.17 | | | | Local | 32 (14, 76) | | 54.1 | 27.9 | | Regional | 22 (7, 123) | | 50.0 | 16.7 | | Distant | 17 (9, 24) | | 36.2 | 15.5 | | Chemotherapy | | 0.26 | | | | None | 23 (18, 29) | | 47.8 | 23.5 | | Chemotherapy, single agent | 14 (5, 52) | | 47.4 | 10.5 | | Chemotherapy, multiple agents | 9 (3, 24) | | 22.2 | 11.1 | | Radiation therapy | | 0.98 | | | | No radiation | 23 (12, 31) | | 46.2 | 22.6 | | Radiation | 22 (12, 28) | | 46.0 | 18.0 | | HIV status | | 0.91 | | | | HIV-positive | 19 (9, 26) | | 41.3 | 22.7 | | HIV-negative | 25 (21, 32) | | 51.5 | 19.1 |
|
|
